Magentiq Eye Secures Series A Funding for AI Gastroenterology Software

Magentiq Eye has successfully completed its Series A funding round, led by aMoon, Israel's largest HealthTech investment fund, announced in a press release. The funding will support the commercialization of Magentiq Eye's AI-powered gastroenterology software, Magentiq-Colo, in the USA and Europe.

Magentiq-Colo is an FDA- and CE-approved software that enhances polyp detection and analysis during colonoscopies, significantly improving adenoma detection rates. The software provides real-time insights and includes features such as polyp-size category and type estimation, along with advanced AI-generated reports.

The investment round also saw participation from Norgine Ventures BV, Nina Capital, Namarel Ventures SL, Nova Capital, and private investors. With this funding, Magentiq Eye aims to accelerate innovation and market access, meeting the growing demand for its diagnostic tools across the U.S. and Europe.

In addition to commercialization efforts, the company is conducting clinical trials for diagnostic tools targeting specialized diseases in the gastrointestinal tract and developing automated quality indicators for GI procedures. The proceeds will also drive global commercial growth through direct sales and partnerships with industry leaders.